Total Payments
$201,707
2024 Payments
$11,086
Companies
12
Transactions
161
Payment Breakdown by Category
Consulting$103,780 (51.5%)
Travel$47,271 (23.4%)
Research$24,963 (12.4%)
Other$22,023 (10.9%)
Food & Beverage$3,670 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $103,780 | 27 | 51.5% |
| Travel and Lodging | $47,271 | 67 | 23.4% |
| Unspecified | $24,963 | 13 | 12.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $12,565 | 2 | 6.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,458 | 5 | 4.7% |
| Food and Beverage | $3,670 | 47 | 1.8% |
Payments by Type
General
$176,744
148 transactions
Research
$24,963
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $66,667 | 58 | $0 (2023) |
| AstraZeneca AB | $49,282 | 21 | $0 (2018) |
| Vertex Pharmaceuticals Incorporated | $28,675 | 15 | $0 (2022) |
| PFIZER INC. | $14,506 | 15 | $0 (2024) |
| Novartis Pharma AG | $10,315 | 8 | $0 (2024) |
| Global Blood Therapeutics, Inc. | $7,019 | 8 | $0 (2022) |
| Shire North American Group Inc | $6,403 | 4 | $0 (2018) |
| AstraZeneca UK Limited | $5,360 | 18 | $0 (2018) |
| Blueprint Medicines Corporation | $5,000 | 1 | $0 (2023) |
| Dova Pharmaceuticals | $4,249 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,086 | 8 | PFIZER INC. ($10,171) |
| 2023 | $11,985 | 10 | NOVARTIS PHARMACEUTICALS CORPORATION ($5,093) |
| 2022 | $18,402 | 16 | Global Blood Therapeutics, Inc. ($7,019) |
| 2021 | $17,224 | 11 | Vertex Pharmaceuticals Incorporated ($9,095) |
| 2020 | $5,843 | 2 | VERTEX PHARMACEUTICALS INCORPORATED ($4,013) |
| 2019 | $24,407 | 35 | Novartis Pharmaceuticals Corporation ($11,858) |
| 2018 | $88,996 | 63 | Novartis Pharmaceuticals Corporation ($43,050) |
| 2017 | $23,766 | 16 | AstraZeneca AB ($19,183) |
All Payment Transactions
161 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/12/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| 05/22/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $191.21 | General |
| Category: HEMATOLOGY | ||||||
| 05/10/2024 | PFIZER INC. | OXBRYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $590.34 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $387.67 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $337.96 | General |
| Category: HEMATOLOGY | ||||||
| 04/13/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $263.66 | General |
| Category: HEMATOLOGY | ||||||
| 01/30/2024 | Novartis Pharma AG | ADAKVEO (Biological) | — | Cash or cash equivalent | $915.00 | Research |
| Study: CSEG101B2201 • Category: HEMATOLOGY | ||||||
| 12/07/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $124.43 | General |
| Category: Genetically Defined Disease | ||||||
| 12/07/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $57.75 | General |
| Category: Genetically Defined Disease | ||||||
| 12/07/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $44.60 | General |
| Category: Genetically Defined Disease | ||||||
| 11/16/2023 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 03/23/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Genetically Defined Disease | ||||||
| 03/14/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Genetically Defined Disease | ||||||
| 02/25/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | ADAKVEO (Drug) | Travel and Lodging | In-kind items and services | $171.77 | General |
| Category: Hematology | ||||||
| 02/25/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | ADAKVEO (Drug) | Food and Beverage | In-kind items and services | $90.41 | General |
| Category: Hematology | ||||||
| 02/24/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | ADAKVEO (Drug) | Food and Beverage | In-kind items and services | $148.53 | General |
| Category: Hematology | ||||||
| 02/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | In-kind items and services | $4,682.15 | General |
| 12/13/2022 | Novartis Pharma AG | ADAKVEO (Biological) | — | Cash or cash equivalent | $1,830.00 | Research |
| Study: CSEG101B2201 • Category: HEMATOLOGY | ||||||
| 12/09/2022 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Food and Beverage | In-kind items and services | $112.13 | General |
| Category: HEMATOLOGY | ||||||
| 11/14/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Travel and Lodging | Cash or cash equivalent | $1,248.17 | General |
| Category: Genetically Defined Disease | ||||||
| 11/14/2022 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $252.31 | General |
| Category: Genetically Defined Disease | ||||||
| 09/28/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $4,280.00 | General |
| 09/12/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $5,640.00 | General |
| Category: Sickle Cell Disease | ||||||
| 09/12/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $51.83 | General |
| Category: Sickle Cell Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $14,648 | 5 |
| CSEG101B2201 | Novartis Pharma AG | $10,315 | 8 |
About Dr. Matthew Heeney, MD
Dr. Matthew Heeney, MD is a Pediatric Hematology-Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437118478.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Heeney, MD has received a total of $201,707 in payments from pharmaceutical and medical device companies, with $11,086 received in 2024. These payments were reported across 161 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($103,780).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Boston, MA
- Active Since 03/20/2006
- Last Updated 08/01/2019
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1437118478
Products in Payments
- ADAKVEO (Biological) $24,401
- BRILINTA (Drug) $20,215
- CRIZANLIZUMAB (Biological) $16,232
- OXBRYTA (Drug) $14,790
- EXJADE (Drug) $14,190
- Doptelet (Drug) $4,249
- PYRUKYND (Drug) $3,392
- ADAKVEO (Drug) $410.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Boston
Mr. Alan Dandrea, Md, MD
Pediatric Hematology-Oncology — Payments: $826,972
Pediatric Hematology-Oncology $826,972
Dr. Leslie Kean, Md/Phd, MD/PHD
Pediatric Hematology-Oncology — Payments: $326,453
Pediatric Hematology-Oncology $326,453
Todd Golub, M.d, M.D
Pediatric Hematology-Oncology — Payments: $247,953
Pediatric Hematology-Oncology $247,953
Dr. Stacy Croteau, Md, MD
Pediatric Hematology-Oncology — Payments: $219,942
Pediatric Hematology-Oncology $219,942
Christine Duncan, M.d, M.D
Pediatric Hematology-Oncology — Payments: $74,023
Pediatric Hematology-Oncology $74,023
Dr. Alan Michelson, M.d, M.D
Pediatric Hematology-Oncology — Payments: $63,616
Pediatric Hematology-Oncology $63,616